Lantern Pharma Reports Fourth Quarter and Year End 2020 Financial Results and Operational Highlights

- RADR® artificial intelligence ("A.I.") platform surpassed 1.2 billion datapoints - Advanced opportunities for LP-184 in glioblastoma, prostate and pancreatic cancers in collaboration with leading cancer research centers - Identified and validated additional genomically-driven cancer indications for LP-184 - Advanced the development of LP-300 with a Phase 2 trial launch in NSCLC planned for Q3 2021 - Initiated Antibody Drug Conjugate ("ADC") program with novel linking and conjugation technology - Strengthened balance sheet following January 2021 public offering of $69.0 million